GTCbio’s 4th Cell & Gene Therapy (CGT) Conference will be held on September 11-12, 2017 in Boston, MA. This meeting will bring together academia and industry to showcase several new technologies emerging in the field of cell and gene therapy. We are pleased to confirm this conference will include keynote presentations by Dr. Richard Gatti, Distinguished Professor in the Departments of Pathology and Laboratory Medicine and Human Genetics at the David Geffen UCLA School of Medicine, and Dr. James Wilson, Professor of Internal Medicine and Pathology, and Laboratory Medicine at the University of Pennsylvania.
The following sessions will be part of CGT 2017.
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Development of Novel Technologies
III. Translational Studies & Lessons Learned
IV. Round Table Discussions
V. Industry Partnering with Academia & CROs to Advance Research
VI. Panel on Funding & Regulatory Challenges
VII. Award Ceremony & Closing Keynote Session – The Future of CGT
The 2017 Advisory Committee
|2017 Advisory Board Members|
|Dongsheng Duan, University of Missouri|
|Richard Gatti, University of California Los Angeles|
|Susan Solomon, New York Stem Cell Foundation|
|Brian Tomkowicz, Johnson & Johnson|
|Denis Rodgerson, GTCbio|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Lonza’s BioResearch products and services range from basic research to drug discovery tools. We offer primary cells and media, Nucleofector™ Technology for difficult-to-transfect cells, novel 3D culture methods and live-cell imaging system. Lonza is well-recognized for its outstanding scientific support team, and dedication to consistent, high performing products.
BioSpherix will be exhibiting the Xvivo System, world’s first and only cytocentric barrier isolator optimized for cells. Economical and practical alternative to cleanrooms for cGMP compliant production of cells for clinical use. Get better contamination, process and quality control. Stop by the BioSpherix booth to learn more about the only total quality platform for cells!
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
C3i is a Montreal-based one-stop-shop solution for the development, translation, and commercialization of cancer immunotherapy. C3i Combines four interacting units: 1. a cGMP Manufacturing Unit for Regenerative Medecine and Cancer Immunotherapy, 2. a Biomarker & Diagnostic Unit, 3. a Clinical Research Unit, and 4. an Innovation and Commercialization Unit.